What is Rocket Pharmaceu's earnings per share (EPS)?

Rocket Pharmaceu (RCKT) reported diluted earnings per share of $-2.01 for fiscal year 2025. This represents a 26.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rocket Pharmaceu Financials

RCKT

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Rocket Pharmaceu (RCKT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Rocket Pharmaceu passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.85x

For every $1 of reported earnings, Rocket Pharmaceu generates $0.85 in operating cash flow (-$190.0M OCF vs -$223.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-122.6x

Rocket Pharmaceu earns $-122.6 in operating income for every $1 of interest expense (-$231.7M vs $1.9M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Rocket Pharmaceu generated $0 in revenue in fiscal year 2025.

EBITDA

-$222.8M

YoY+16.2%

Rocket Pharmaceu's EBITDA was -$222.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.2% from the prior year.

Net Income

-$223.1M

YoY+13.8%

Rocket Pharmaceu reported -$223.1M in net income in fiscal year 2025. This represents an increase of 13.8% from the prior year.

EPS (Diluted)

$-2.01

YoY+26.4%

Rocket Pharmaceu earned $-2.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 26.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$190.5M

YoY+11.7%

Rocket Pharmaceu generated -$190.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 11.7% from the prior year.

Cash & Debt

$77.6M

YoY-52.6%

5Y CAGR-23.6%

10Y CAGR-0.3%

Rocket Pharmaceu held $77.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

108M

YoY+1.8%

5Y CAGR+12.2%

Rocket Pharmaceu had 108M shares outstanding in fiscal year 2025. This represents an increase of 1.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-80.5%

YoY-24.6pp

5Y CAGR-52.8pp

10Y CAGR+357.0pp

Rocket Pharmaceu's ROE was -80.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 24.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$142.0M

YoY-17.1%

5Y CAGR+6.1%

10Y CAGR+27.5%

Rocket Pharmaceu invested $142.0M in research and development in fiscal year 2025. This represents a decrease of 17.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$440K

YoY-92.5%

5Y CAGR-53.7%

10Y CAGR+0.7%

Rocket Pharmaceu invested $440K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 92.5% from the prior year.

RCKT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$0	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$142.0M-17.1%	$171.2M-8.1%	$186.3M+12.5%	$165.6M+32.0%	$125.5M+19.0%	$105.4M
SG&A Expenses	$86.5M-15.2%	$102.0M+39.1%	$73.3M+24.7%	$58.8M+40.7%	$41.8M+44.7%	$28.9M
Operating Income	-$231.7M+15.2%	-$273.2M-5.2%	-$259.7M-15.7%	-$224.3M-34.1%	-$167.2M-24.5%	-$134.3M
Interest Expense	$1.9M+0.3%	$1.9M+0.6%	$1.9M+0.7%	$1.9M-37.5%	$3.0M-57.3%	$7.0M
Income Tax	$0	$0	$0	N/A	N/A	N/A
Net Income	-$223.1M+13.8%	-$258.7M-5.4%	-$245.6M-10.7%	-$221.9M-31.2%	-$169.1M-21.0%	-$139.7M
EPS (Diluted)	$-2.01+26.4%	$-2.73+6.5%	$-2.92+10.4%	$-3.26-22.1%	$-2.67-6.0%	$-2.52

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	$0	$0	$0	N/A	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$34.1M-20.1%	$42.7M+18.7%	$35.9M	N/A	$42.3M-8.7%	$46.3M+2.5%	$45.2M
SG&A Expenses	N/A	$18.4M-26.7%	$25.0M-12.0%	$28.4M	N/A	$27.1M-0.9%	$27.4M+23.6%	$22.1M
Operating Income	N/A	-$52.2M+26.6%	-$71.1M-10.5%	-$64.4M	N/A	-$69.4M+5.8%	-$73.7M-9.4%	-$67.4M
Interest Expense	N/A	$473K0.0%	$473K+0.2%	$472K	N/A	$471K0.0%	$471K0.0%	$471K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$50.3M+27.0%	-$68.9M-12.4%	-$61.3M	N/A	-$66.7M+4.2%	-$69.6M-12.2%	-$62.1M
EPS (Diluted)	N/A	$-0.45+27.4%	$-0.62-10.7%	$-0.56	N/A	$-0.71+4.1%	$-0.74-12.1%	$-0.66

RCKT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$330.4M-37.4%	$527.7M-6.8%	$566.3M+2.6%	$551.8M+11.0%	$497.0M-15.9%	$590.8M
Current Assets	$192.7M-49.0%	$378.2M0.0%	$378.2M+3.9%	$364.1M-7.1%	$392.1M-19.6%	$487.3M
Cash & Equivalents	$77.6M-52.6%	$163.6M+192.7%	$55.9M-60.2%	$140.5M-39.6%	$232.7M-21.7%	$297.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$39.2M0.0%	$39.2M0.0%	$39.2M-0.1%	$39.2M+27.2%	$30.8M0.0%	$30.8M
Total Liabilities	$53.2M-17.4%	$64.5M-12.6%	$73.8M+18.7%	$62.1M+46.9%	$42.3M-51.6%	$87.3M
Current Liabilities	$30.2M-25.8%	$40.7M-16.1%	$48.5M+23.8%	$39.2M+76.7%	$22.2M-32.0%	$32.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$277.2M-40.2%	$463.2M-6.0%	$492.6M+0.6%	$489.7M+7.7%	$454.7M-9.7%	$503.5M
Retained Earnings	-$1.4B-18.3%	-$1.2B-27.0%	-$959.4M-34.4%	-$713.8M-45.1%	-$491.9M-52.4%	-$322.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$330.4M-10.2%	$368.0M-12.6%	$421.0M-10.6%	$471.1M-10.7%	$527.7M+34.0%	$393.7M-11.8%	$446.4M-10.6%	$499.4M
Current Assets	$192.7M-15.3%	$227.7M-17.9%	$277.2M-14.6%	$324.5M-14.2%	$378.2M+56.4%	$241.8M-17.4%	$292.7M-15.2%	$345.2M
Cash & Equivalents	$77.6M+2.1%	$75.9M+131.4%	$32.8M-34.1%	$49.8M-69.6%	$163.6M+149.4%	$65.6M+69.9%	$38.6M+9.4%	$35.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M
Total Liabilities	$53.2M-2.1%	$54.4M-18.6%	$66.8M+13.3%	$58.9M-8.6%	$64.5M+0.9%	$63.9M+3.5%	$61.8M+6.6%	$57.9M
Current Liabilities	$30.2M-3.1%	$31.2M-28.2%	$43.4M+22.9%	$35.3M-13.2%	$40.7M+1.8%	$40.0M+6.4%	$37.6M+14.1%	$33.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$277.2M-11.6%	$313.7M-11.4%	$354.2M-14.1%	$412.1M-11.0%	$463.2M+40.5%	$329.8M-14.3%	$384.6M-12.9%	$441.5M
Retained Earnings	-$1.4B-3.0%	-$1.4B-3.7%	-$1.3B-5.4%	-$1.3B-5.0%	-$1.2B-5.2%	-$1.2B-6.1%	-$1.1B-6.8%	-$1.0B

RCKT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$190.0M+9.4%	-$209.7M-7.6%	-$194.9M-9.4%	-$178.1M-47.0%	-$121.2M-62.3%	-$74.6M
Capital Expenditures	$440K-92.5%	$5.9M-64.3%	$16.4M+96.6%	$8.4M+9.7%	$7.6M-63.0%	$20.6M
Free Cash Flow	-$190.5M+11.7%	-$215.6M-2.0%	-$211.4M-13.3%	-$186.5M-44.8%	-$128.8M-35.2%	-$95.2M
Investing Cash Flow	$103.8M-21.2%	$131.7M+234.3%	-$98.1M-41.5%	-$69.3M-467.7%	$18.9M+119.5%	-$96.6M
Financing Cash Flow	$148K-99.9%	$185.7M-10.9%	$208.4M+34.2%	$155.3M+312.1%	$37.7M-86.7%	$283.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0-100.0%	$72K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$34.8M+30.9%	-$50.4M-3.0%	-$49.0M+12.2%	-$55.8M-18.8%	-$46.9M+9.9%	-$52.1M+3.2%	-$53.8M+5.3%	-$56.9M
Capital Expenditures	$80K+248.1%	-$54K-208.0%	$50K-86.3%	$364K+17.8%	$309K-80.5%	$1.6M-17.7%	$1.9M-5.2%	$2.0M
Free Cash Flow	-$34.9M+30.8%	-$50.5M-3.0%	-$49.0M+12.7%	-$56.2M-18.8%	-$47.3M+12.0%	-$53.7M+3.7%	-$55.8M+5.3%	-$58.9M
Investing Cash Flow	$36.4M-61.1%	$93.6M+194.8%	$31.8M+154.7%	-$58.0M-53.2%	-$37.9M-148.0%	$78.9M+41.9%	$55.6M+58.8%	$35.0M
Financing Cash Flow	$0+100.0%	-$67K-131.2%	$215K	$0-100.0%	$182.8M+103791.5%	$176K-88.5%	$1.5M+29.2%	$1.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RCKT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-80.5%-24.6pp	-55.9%-6.0pp	-49.9%-4.5pp	-45.3%-8.1pp	-37.2%-9.4pp	-27.7%
Return on Assets	-67.5%-18.5pp	-49.0%-5.7pp	-43.4%-3.2pp	-40.2%-6.2pp	-34.0%-10.4pp	-23.6%
Current Ratio	6.38-2.9	9.30+1.5	7.80-1.5	9.29-8.4	17.69+2.7	14.94
Debt-to-Equity	0.19+0.1	0.14-0.0	0.15+0.0	0.13+0.0	0.09-0.1	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-16.1%+3.4pp	-19.5%-4.6pp	-14.9%	N/A	-20.2%-2.1pp	-18.1%-4.1pp	-14.1%
Return on Assets	N/A	-13.7%+2.7pp	-16.4%-3.4pp	-13.0%	N/A	-17.0%-1.4pp	-15.6%-3.2pp	-12.4%
Current Ratio	6.38-0.9	7.30+0.9	6.39-2.8	9.19-0.1	9.30+3.2	6.05-1.7	7.79-2.7	10.47
Debt-to-Equity	0.19+0.0	0.17-0.0	0.19+0.0	0.140.0	0.14-0.1	0.19+0.0	0.16+0.0	0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Larimar Therapeutics Inc LRMR

$486.2M

Immuneering Corp IMRX

$344.6M

AUTOLUS THERAPEUTICS PLC AUTL

$367.3M

Diamedica Therapeutics Inc DMAC

$345.0M

Assembly Bioscie ASMB

$466.8M

Frequently Asked Questions

What is Rocket Pharmaceu's annual revenue?

Rocket Pharmaceu (RCKT) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Rocket Pharmaceu profitable?

No, Rocket Pharmaceu (RCKT) reported a net income of -$223.1M in fiscal year 2025.

What is Rocket Pharmaceu's EBITDA?

Rocket Pharmaceu (RCKT) had EBITDA of -$222.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Rocket Pharmaceu's return on equity (ROE)?

Rocket Pharmaceu (RCKT) has a return on equity of -80.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rocket Pharmaceu's free cash flow?

Rocket Pharmaceu (RCKT) generated -$190.5M in free cash flow during fiscal year 2025. This represents a 11.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Rocket Pharmaceu's operating cash flow?

Rocket Pharmaceu (RCKT) generated -$190.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Rocket Pharmaceu's total assets?

Rocket Pharmaceu (RCKT) had $330.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Rocket Pharmaceu's capital expenditures?

Rocket Pharmaceu (RCKT) invested $440K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Rocket Pharmaceu spend on research and development?

Rocket Pharmaceu (RCKT) invested $142.0M in research and development during fiscal year 2025.

How many shares does Rocket Pharmaceu have outstanding?

Rocket Pharmaceu (RCKT) had 108M shares outstanding as of fiscal year 2025.

What is Rocket Pharmaceu's current ratio?

Rocket Pharmaceu (RCKT) had a current ratio of 6.38 as of fiscal year 2025, which is generally considered healthy.

What is Rocket Pharmaceu's debt-to-equity ratio?

Rocket Pharmaceu (RCKT) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rocket Pharmaceu's return on assets (ROA)?

Rocket Pharmaceu (RCKT) had a return on assets of -67.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rocket Pharmaceu's cash runway?

Based on fiscal year 2025 data, Rocket Pharmaceu (RCKT) had $77.6M in cash against an annual operating cash burn of $190.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Rocket Pharmaceu's Piotroski F-Score?

Rocket Pharmaceu (RCKT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rocket Pharmaceu's earnings high quality?

Rocket Pharmaceu (RCKT) has an earnings quality ratio of 0.85x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Rocket Pharmaceu cover its interest payments?

Rocket Pharmaceu (RCKT) has an interest coverage ratio of -122.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.